IP Library › Granted Patent US 12,433,881
Granted Patent B2
US 12,433,881 · App. 18/649,759 · Granted Oct 7, 2025

Nicotine tablet

Inventors: Bruno Provstgaard Nielsen (Vejle Øst, DK); Kent Albin Nielsen (Brande, DK)
Assignee: Fertin Pharma A/S
A61K31/465A61K9/0056A61K9/006A61K9/2009A61K9/2027A61K9/2095A61P25/34
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,433,881
App. No.
18/649,759
Granted
Oct 7, 2025
Kind
B2
Abstract

The invention relates to an orally disintegrating nicotine tablet for nicotine craving relief comprising a pressed powder formulation, the tablet being designed to disintegrate within a period of less than 60 seconds upon oral administration, the powder formulation comprising an amount of nicotine and a pH regulating agent.

Claims (27)

1. An orally disintegrating nicotine tablet for nicotine craving relief comprising a pressed powder formulation, wherein the tablet disintegrates within a period of less than 210 seconds upon oral administration, wherein the pressed powder formulation comprises an amount of nicotine, a pH regulating agent, at least one polyol, and a disintegrant, wherein the tablet comprises the polyol in an amount of more than 40% by weight of the tablet, wherein the disintegrant comprises superdisintegrant in an amount of 1 to 10% by weight of the tablet, wherein the formulation provides a peak saliva pH of more than 7.6 during the first 120 seconds upon oral administration, and wherein the tablet reduces the side effect of burning.

2. The tablet according to claim 1 , wherein the superdisintegrant is selected from the group consisting of crosslinked cellulose, crosslinked polyvinyl pyrrolidone (PVP), crosslinked starch, crosslinked alginic acid, natural superdisintegrants, calcium silicate, and combinations thereof.

3. The tablet according to claim 1 , wherein the superdisintegrant comprises at least one of crospovidone, sodium starch glycolate, and croscarmellose.

4. The tablet according to claim 1 , wherein the disintegrant further comprises disintegrant selected from the group consisting of starch, pregelatinated starch, modified starch, alginates, ion-exchange resin, and combinations thereof.

5. The tablet according to claim 1 , wherein the tablet is designed to disintegrate within a period of less than 60 seconds upon oral administration.

6. The tablet according to claim 1 , wherein the tablet comprises nicotine in an amount of at least 0.5 mg.

7. The tablet according to claim 1 , wherein said nicotine is provided as a nicotine salt.

8. The tablet according to claim 7 , wherein the nicotine salt is selected from the group consisting of nicotine ascorbate, nicotine aspartate, nicotine benzoate, nicotine monotartrate, nicotine bitartrate, nicotine chloride, nicotine citrate, nicotine fumarate, nicotine gensitate, nicotine lactate, nicotine mucate, nicotine laurate, nicotine levulinate, nicotine malate nicotine perchlorate, nicotine pyruvate, nicotine salicylate, nicotine sorbate, nicotine succinate, nicotine zinc chloride, nicotine sulfate, nicotine tosylate, nicotine salt hydrates, and any combination thereof.

9. The tablet according to claim 1 , wherein said nicotine is provided as a complex between nicotine and an ion exchange resin.

10. The tablet according to claim 1 , wherein said nicotine is provided in ionic complex with at least one mucoadhesive water-soluble anionic polymer.

11. The tablet according to claim 1 , wherein the tablet is a sublingual tablet.

12. The tablet according to claim 1 , wherein the tablet is pressed at a pressure of 2-20 kN.

13. The tablet according to claim 1 , wherein the formulation provides a peak saliva concentration of nicotine of more than 0.3 mg/mL and a peak saliva pH of more than 8 during the first 120 seconds upon oral administration.

14. The tablet according to claim 1 , wherein the tablet comprises sodium stearyl fumarate (SSF) as a lubricant.

15. The tablet according to claim 1 , wherein the tablet comprises pH regulating agent in an amount of at least 2.7 percent by weight of said tablet.

16. The tablet according to claim 1 , wherein the tablet has a weight of 25 to 200 mg.

17. The tablet according to claim 1 , wherein the at least one polyol is selected from the group consisting of sorbitol, erythritol, xylitol, maltitol, mannitol, lactitol, isomalt, and any combination thereof.

18. The tablet according to claim 1 , wherein the at least one polyol is mannitol.

19. An orally disintegrating nicotine tablet for nicotine craving relief comprising a pressed powder formulation, wherein the tablet disintegrates within a period of less than 210 seconds upon oral administration, wherein the pressed powder formulation comprises an amount of nicotine, a pH regulating agent, at least one filler, and a disintegrant, wherein the tablet comprises the filler in an amount of more than 40% by weight of the tablet, wherein the disintegrant comprises superdisintegrant in an amount of 1 to 10% by weight of the tablet, wherein the formulation provides a peak saliva pH of more than 7.6 during the first 120 seconds upon oral administration, and wherein the tablet reduces the side effect of burning.

20. The tablet according to claim 19 , wherein the filler comprises at least one polyol.

21. The tablet according to claim 19 , wherein the filler is selected from the group consisting of polyols, magnesium carbonate, calcium carbonate, sodium sulphate, ground limestone, silicate compounds, kaolin, clay, aluminum oxide, silicium oxide, talc, mono-calcium phosphate, di-calcium phosphate, tri-calcium phosphates, cellulose polymers, fibers, microcrystalline cellulose, and combinations thereof.

22. An orally disintegrating nicotine tablet for nicotine craving relief comprising a pressed powder formulation, wherein the tablet disintegrates within a period of less than 210 seconds upon oral administration, wherein the pressed powder formulation comprises an amount of nicotine, a pH regulating agent, at least one polyol, and a disintegrant,

wherein the tablet comprises the polyol in an amount of more than 40% by weight of the tablet,

wherein the tablet comprises disintegrant in an amount of at least 1% by weight of the tablet, and

wherein the formulation provides a peak saliva pH of more than 7.6 during the first 120 seconds upon oral administration.

23. A method of alleviation of nicotine craving by administering said orally disintegrating nicotine tablet according to claim 1 .

24. The tablet according to claim 1 , wherein the tablet comprises microcrystalline cellulose in an amount of 1 to 10% by weight of the tablet.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Apr 29, 2024
From: NIELSEN, BRUNO PROVSTGAARD; NIELSEN, KENT ALBIN
To: FERTIN PHARMA A/S
Reel/Frame 067259/0349 →
Priority Claims (1)
DK PA 2017 70925 · Dec 8, 2017 · national
Continuity (3)
Continuation 18348891 · Jul 7, 2023
Continuation 16213641 · Dec 7, 2018
Related Publication 20240285610A1 · Aug 29, 2024
References Cited (91)
US 4866046A · Amer · 1989 [cited by applicant]
US 5662920A · Santus · 1997 [cited by applicant]
US 5810018A · Monte · 1998 [cited by applicant]
US 5935604A · Illum · 1999 [cited by applicant]
US 6248760B1 · Wilhelmsen · 2001 [cited by applicant]
US 7387788B1 · Carrara et al. · 2008 [cited by applicant]
US 8529939B2 · Masters et al. · 2013 [cited by applicant]
US 8597679B2 · Kolter et al. · 2013 [cited by applicant]
US 20010016593A1 · Wilhelmsen · 2001 [cited by applicant]
US 20020002189A1 · Smith et al. · 2002 [cited by applicant]
US 20020136767A1 · Sparks et al. · 2002 [cited by applicant]
US 20060057207A1 · Ziegler · 2006 [cited by applicant]
US 20070269386A1 · Steen et al. · 2007 [cited by applicant]
US 20080286341A1 · Andersson et al. · 2008 [cited by applicant]
US 20100108059A1 · Axelsson et al. · 2010 [cited by applicant]
US 20100178353A1 · Mezaache et al. · 2010 [cited by applicant]
US 20110206621A1 · Agarwal et al. · 2011 [cited by applicant]
US 20110274628A1 · Borschke · 2011 [cited by applicant]
US 20130177646A1 · Hugerth et al. · 2013 [cited by applicant]
US 20130289079A1 · Chen · 2013 [cited by applicant]
US 20140328973A1 · Nielsen · 2014 [cited by applicant]
US 20150080442A1 · McCarty · 2015 [cited by applicant]
US 20150096576A1 · Gao et al. · 2015 [cited by applicant]
US 20170165252A1 · Mua et al. · 2017 [cited by applicant]
US 20170172995A1 · Repaka et al. · 2017 [cited by applicant]
US 20170189388A1 · Arnold · 2017 [cited by applicant]
US 20190160019A1 · Nielsen · 2019 [cited by applicant]
US 20190174812A1 · Nielsen et al. · 2019 [cited by applicant]
US 20190175581A1 · Nielsen et al. · 2019 [cited by applicant]
US 20200397691A1 · Nielsen et al. · 2020 [cited by applicant]
US 20210345656A1 · Nielsen et al. · 2021 [cited by applicant]
US 20230158011A1 · Nielsen · 2023 [cited by applicant]
US 20230346768A1 · Nielsen · 2023 [cited by applicant]
CA 2831715 · 2012 [cited by applicant]
EP 1366759A1 · 2003 [cited by applicant]
EP 2177213A1 · 2010 [cited by applicant]
EP 2446881A1 · 2012 [cited by applicant]
JP 2006518761A · 2006 [cited by applicant]
JP 2010526876A · 2010 [cited by applicant]
JP 2011519862A · 2011 [cited by applicant]
JP 2012505878A · 2012 [cited by applicant]
JP 2014503539A · 2014 [cited by applicant]
JP 2015503581A · 2015 [cited by applicant]
RU 2153338C2 · 2000 [cited by applicant]
RU 2608902C2 · 2017 [cited by applicant]
TW 201318650A1 · 2013 [cited by applicant]
WO WO2002085119A1 · 2002 [cited by applicant]
WO WO03055486A1 · 2003 [cited by applicant]
WO WO2003055486A1 · 2003 [cited by applicant]
WO WO2004075877A1 · 2004 [cited by applicant]
WO WO2007133140A1 · 2007 [cited by applicant]
WO WO2008037470 · 2008 [cited by applicant]
WO WO2008037470A1 · 2008 [cited by applicant]
WO WO2008082808A1 · 2008 [cited by applicant]
WO WO2008140371A1 · 2008 [cited by applicant]
WO WO2008140372A1 · 2008 [cited by applicant]
WO WO2009007771A1 · 2009 [cited by applicant]
WO WO2009134947A1 · 2009 [cited by applicant]
WO WO2010044736A1 · 2010 [cited by applicant]
WO WO2012085043A2 · 2012 [cited by applicant]
WO WO2012134380A1 · 2012 [cited by applicant]
WO WO2013091631A1 · 2013 [cited by applicant]
WO WO2013103318A1 · 2013 [cited by applicant]
WO WO2019110072A1 · 2019 [cited by applicant]
“Cellulose, Microcrystalline,” 2006. Eds. Rowe et al. In Handbook of Pharmaceutical Excipients, Fifth Edition, Pharmaceutical Press. London, England. pp. 132-135, 26 pages. [cited by applicant]
“Crospovidone ED”. Nov. 2002. In: Rowe RC, Sheskey PJ, Weller PJ, eds. Handbook of Pharmaceutical Excipients, Pharmaceutical Press, London, UK, p. 184, XP002719370. 2 pages. [cited by applicant]
“Crospovidone,” 2006. Eds. Rowe et al. In Handbook of Pharmaceutical Excipients, Fifth Edition, Pharmaceutical Press. London, England, pp. 214-216, 26 pages. [cited by applicant]
“Guidance for Industry Oral Disintegrating Tablets,” Dec. 2008. U.S. Department of Health and Human Services Food and Drug Administration Center for Drug Evaluation and Research, 6 pages. [cited by applicant]
“Kollidon® CL, Kollidon® CL-F, Kollidon® CL-SF, Kollidon® CL-M: Super-disintegrants and dissolution enhancers”. Brochure from BASF The Chemical Company. www.pharma-solutions.basf.com, downloaded at least by May 11, 2022… [cited by applicant]
“Ludiflash® The taste of sucess: Making tablets as smooth as ice cream”. Brochure from BASF The Chemical Company. www.pharma-ingredients.basf.com, downloaded at least by May 11, 2022. 12 pages. [cited by applicant]
“Mannitol” Jan. 2006. In: Rowe RC, Sheskey PJ, Weller PJ, eds. Handbook of Pharmaceutical Excipients, Pharmaceutical Press, London, UK, pp. 449-453, XP002537758, 5 pages. [cited by applicant]
“Mannitol,” 2006. Eds. Rowe et al. In Handbook of Pharmaceutical Excipients, Fifth Edition, Pharmaceutical Press. London, England. pp. 449-454, 28 pages. [cited by applicant]
Conway, “Solid Dosage Forms”, Mar. 2008. Ed. S. Cox In Pharmaceutical Manufacturing Handbook, Production and Processes, Chapter 4.1.11: Excerpt pp. 259-263. [cited by applicant]
Davies, “Oral Solid Dosage Forms,” 2009. Ed. M. Gibson In Pharmaceutical Preformulation and Formulation, A Practical Guide from Candidate Drug Selection to Commercial Dosage Form, Second Edition, Chapter 11: Excerpt: pp… [cited by applicant]
Deshmukh, “Mouth Dissolving Drug Delivery System: A Review,” Jan. 2012. International Journal of PharmTech Research, 4(1): 412-421. [cited by applicant]
Dey et al., “Orodispersible tablets: A trend in drug delivery,” Jul. 2010. Journal of Natural Science, Biology and Medicine, 1(1): 1-5. [cited by applicant]
European Office Action dated Mar. 3, 2021 in European Application No. 18821992.7, a foreign corresponding application of U.S. Appl. No. 16/213,641, 8 pages. [cited by applicant]
European Office Action dated Mar. 3, 2021 in European Application No. 18821993.5, a foreign corresponding application of U.S. Appl. No. 16/213,678, 9 pages. [cited by applicant]
European Oral Summons dated Sep. 6, 2021 in European Application No. 188219933.5, a foreign corresponding application of U.S. Appl. No. 16/213,678, 17 pages. [cited by applicant]
European Search Report dated Sep. 14, 2021 in European Application No. 21182000.6, a foreign corresponding application of U.S. Appl. No. 16/213,641, 12 pages. [cited by applicant]
Hickman, “Melt in the Mouth,” Nov. 2017, The Medicine Maker, Discovery and Development, downloaded Jan. 14, 2023 from https://themedicinemaker.com/discovery-development/melt-in-the-mouth, 9 pages. [cited by applicant]
International Search Report and Written Opinion dated Mar. 14, 2019 in International Application No. PCT/DK2018/050338, 12 pages. [cited by applicant]
International Search Report and Written Opinion dated Mar. 14, 2019 in International Application No. PCT/DK2018/050339, 12 pages. [cited by applicant]
International Search Report and Written Opinion dated May 13, 2019 in International Application No. PCT/DK2018/050337, 15 pages. [cited by applicant]
Japanese Office Action dated Nov. 29, 2022 in Japanese Application No. JP2020-529346, a foreign corresponding application of U.S. Appl. No. 16/213,641, 8 pages. [cited by applicant]
Lafleur, et. al., “Comprehensive mucoadhesive study of anionic polymers and their derivative”, European Polymer Journal, vol. 93, Aug. 2017, pp. 314-322. [cited by applicant]
Notice of Oppisition mailed May 11, 2022 in European Application No. 18821992.7, a foreign corresponding Application of U.S. Appl. No. 16/213,641, 3 pages. [cited by applicant]
Patil et al., “A Review on Mouth Dissolving Tablet,” 2017. Journal of Applied Pharmaceutical Research, 5(2): 9-15. [cited by applicant]
Russian Office Action mailed Dec. 17, 2021 in Russian Application No. 2020122405/04(038512), a foreign corresponding application of U.S. Appl. No. 16/213,641, 5 pages. [cited by applicant]
Shahab et al., “Novel Delivery Systems for Nicotine Replacement Therapy as an Aid to Smoking Cessation and for Harm Reduction: Rationale, and Evidence for Advantages over Existing Systems,” CNS Drugs (2013) 27:1007-1019. [cited by applicant]
Tillotson, “Comparison of Directly Compressible Drug Delivery Systems for Orally Disintegrating Tablets,” 2014. SPI Pharma, 2 pages. [cited by applicant]